Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07230925

Study of the Rate of Progression of Cerebral Ischemia in Afro-Caribbeans

To compare the progression of cerebral ischemia from HF in Afro-Caribbean patients admitted to the CHUG to that of patients from Nantes included in the national ETIS registry.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

mpare the progression of cerebral ischemia of IC in Afro-Caribbean patients admitted to the CHUG with that of patients from Nantes included in the national register ETIS.

Secondary outcomes: Stroke is a sudden interruption of blood flow in the brain. Among the types of stroke, cerebral infarction is the most common (80% of cases). Cerebral infarction (CI) is a sudden disruption of brain circulation due to the occlusion of an artery by a clot. Large vessel occlusions (OLV) of the brain represent 30-40% of occlusions and are frequently associated with poor prognosis. Mechanical thrombectomy (MT) involves the extraction of the intra-arterial thrombus. Often performed in conjunction with intravenous thrombolysis (TIV), it has become the preferred treatment for OLV. However, not all patients with OLV are eligible for TM. It is recognized that for the same occlusion site, the rate of progression of HF varies from individual to individual. There are two categories of patients: the "fast progressor" and the "slow progressor". Patients referred to as "fast progressor" have a higher volume CI than "slow progressors" for the same time delay between onset of symptoms and imaging. The "fast progressor" profile is usually associated with an unfavourable functional prognosis. In the study by Rocha et al (ref. n°8), assessing the prevalence and distribution of ischemic volume progression rate in patients with OLV; 58% of patients had ischemic volume 30 mL and 72% had ischemic volume 70 mL within 24 hours after the onset of stroke. These patients were characterized as "slow progressors".

In 2022, a retrospective preliminary study was carried out at the Guadeloupe University Hospital and allowed for a comparison of patients treated within the institution with those of patients from the ETIS Register recording thrombectomies performed nationally. The comparison between the two populations shows that patients who have suffered a stroke in Guadeloupe are of type "fast progressor".

We hypothesize that the Afro-Caribbean patients admitted to CHUG for IC would be mostly "fast progressors".

The rate of progression will be determined using brain imaging from the measurement of ischemia volume. This faster progression could be explained by several factors including (1) differences in blood supply between the two populations; (2) environmental and climatic conditions and (3) epigenetic and genetic factors

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

  • inclusion criteria:
  • Patients aged 18 and over, admitted for IC due to LVO verified by medical imaging and hospitalized in neurology.
  • Patients residing in Guadeloupe
  • Afro-Caribbean patients: of African ancestry.
  • Emergency inclusion, with exemption from obtaining consent due to the immediate life-threatening emergency situation of the patient (Article L1122-1-3 of the French Public Health Code); as soon as possible, consent to continue will be sought from the patient or, if applicable, from a relative or a trusted person.
  • Patients affiliated to a social security scheme or equivalent
  • exclusion criteria:
  • Patients under 18 years old
  • Non-resident patients in Guadeloupe
  • Protected persons (articles L1121-5, L1121-6 and L121-8 of the Public Health Code): pregnant or breastfeeding women, persons deprived of their liberty, under guardianship or curatorship)
  • Withdrawal of consent during the study
  • Patients not affiliated to a social security or equivalent scheme

Treatment and study plan

No interventions

Other

No interventions

Primary outcomes

  1. progression of cerebral ischemia of IC in Afro-Caribbean patients admitted to the CHUG with that of patients from Nantes included in the national register ETIS

    Time frame: baseline, day 1,2,3,4 an day 90

    Compare the progression of cerebral ischemia of IC in Afro-Caribbean patients admitted to the CHUG with that of patients from Nantes included in the national register ETIS

Secondary outcomes

  1. Characterizing the profile of Afro-Caribbean patients

    Time frame: baseline

    • the collateral imaging substitutions in patients of CHUG and CHU de Nantes. The collateral network will be evaluated either by perfusion imaging (Tmax > 6s) or by digitized arterial angiography in a thrombectomy room on the day of stroke according to the ASITN/SIR classification (J0).
  2. Characterizing the profile of Afro-Caribbean patients

    Time frame: baseline

    impact of environmental conditions on ischemia progression rate at Guadeloupe Hospital

  3. Characterizing the profile of Afro-Caribbean

    Time frame: at the end of the suty

    the effect of ischemia-reperfusion induced inflammatory response on ischemia volume

Study contacts

Contact information is provided by the study sponsor or research team.

Eunice NUBRET

CONTACT

[email protected]

Valérie HAMONY-SOTER

CONTACT

[email protected]

+590590934686

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de la Guadeloupe

Other

Registry information

Acronym: VESPERALS

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Nov 17, 2025
Registry last updated
Nov 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.